Invivyd Q2 FY26 net loss widens to $44.4 million; revenue rises 21% to $14.3 million

IVVD•2026-08-13

Trial updates

DECLARATION enrollment is complete, with top-line data planned later in Q3 2026.

LIBERTY is fully dosed, with data expected late in Q3 2026.

Q2 financial results

Invivyd posted Q2 2026 net product revenue of $14.3 million, up 21% on higher patient demand.

Net loss widened to $44.4 million; loss per share was $0.14.

Research and development expenses jumped to $29.4 million due to higher contract research costs for the DECLARATION and LIBERTY trials.

Selling, general and administrative expenses climbed to $29.5 million on higher personnel, communications and commercial-related costs. Cash ended at $160.1 million.

Invivyd Q2 FY26 net loss widens to $44.4 million; revenue rises 21% to $14.3 million

Trial updates

Q2 financial results

Related News

ContextLogic Holdings Q2 revenue flat as higher prices offset lower volumes

Abacus Global Management Announces $100 Million Share Repurchase Program

AIG Launches Parametric Cloud Outage Solution For Cyber Insurance Protection

Kraig Biocraft FY26 Q2 net loss widens 25.26% to $909,535; revenue remains nil

Applied Energetics Q2 FY26 net loss widens 13.02% to $4.28 million; revenue drops 11.85% to $62,000